Schedule 13G ownership disclosure

Corvus Pharmaceuticals Inc

Common Stock, par value $0.0001 per share · CUSIP: 221015100

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Samlyn Capital, LLC

    Shares: 6,667,105.00 · Class: 9.8%

  • Samlyn, LP

    Shares: 6,667,105.00 · Class: 9.8%

  • Robert Pohly

    Shares: 6,667,105.00 · Class: 9.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000919574-25-001469
Form type
SCHEDULE 13G/A
Filer
Corvus Pharmaceuticals, Inc.
CIK
CIK 1626971
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub